Serum levels of insulin-like growth factor (IGF) and its carrier protein in various metabolic disorders
- 1 December 1980
- journal article
- research article
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 95 (4), 505-517
- https://doi.org/10.1530/acta.0.0950505
Abstract
The levels of insulin-like growth factors (IGF), two somatomedin-like polypeptides of human serum and of their carrier protein were determined in sera of patients with various metabolic disorders. IGF was measured by 4 different methods (fat pad and fat cell assay and competitive protein binding assay measuring total IGF, and a radioimmunoassay for IGF I) after extraction by acidic gel filtration on Sephadex G-50. This procedure is necessary to separate IGF from the carrier protein, which interferes with all of these assays. 1) In normal serum, immunoreactive IGF I accounts for one third of total IGF determined by the fat pad assay, but only for one fifth to one sixth of immunoreactive IGF I + II. 2) In acromegalics total IGF was increased 1.5- (protein binding and fat cell assay) to 2-fold (fat pad assay), but the increase was solely due to immunoreactive IGF I, which was ∼ 5-times above normal. The IGF binding activity was not elevated. Total IGF and IGF binding were decreased in hypopituitarism, Laron-type dwarfism and in liver cirrhosis. Immunoreactive IGF I was more drastically reduced in these diseases than total IGF. Apparently, only IGF I is under growth hormone control. The liver seems to be involved in the production of IGF. 3) No elevation of total IGF was found in patients with extrapancreatic tumour hypoglycaemia, but IGF binding was reduced. Immunoreactive IGF I was decreased in 5 of 10 patients. These results suggest that tumour hypoglycaemia in our patients is unlikely to be caused by increased IGF levels. 4) In patients with hyperprolactinaemia neither total IGF nor immunoreactive IGF I were elevated, and IGF binding was unchanged. 5) In newly detected insulin-deficient juvenile diabetics total IGF and immunoreactive IGF I levels were within the normal range, although the variation was greater than in normal subjects. However, IGF binding was markedly decreased.This publication has 22 references indexed in Scilit:
- SOMATOMEDIN PRODUCTION IN NORMAL ADULTS AND CIRRHOTIC PATIENTSActa Endocrinologica, 1977
- Serum Somatomedin Peptides Measured by Somatomedin A Radioreceptor Assay in Chronic Liver DiseaseJournal of Clinical Endocrinology & Metabolism, 1977
- Estimation of Somatomedin-C Levels in Normals and Patients with Pituitary Disease by RadioimmunoassayJCI Insight, 1977
- DECREASE OF NON-SUPPRESSIBLE INSULIN-LIKE ACTIVITY AFTER PANCREATECTOMY AND NORMALIZATION BY INSULIN THERAPYActa Endocrinologica, 1977
- Lack of a Simple Relationship Between Endogenous Growth Hormone and NSILA-s Related PeptidesJournal of Clinical Endocrinology & Metabolism, 1977
- Adrenocortical Carcinoma and Hypoglycemia: Evidence for Production of Nonsuppressible Insulin-Like Activity by the TumorJournal of Clinical Endocrinology & Metabolism, 1977
- Determination of Nonsuppressible Insulin-Like Activity in Human Serum by a Sensitive Protein-Binding AssayClinical Chemistry, 1977
- Radioimmunoassay for Non-Suppressible Insulin-Like ActivityHormone Research, 1976
- METABOLISM OF ISOLATED FAT CELLS .I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM + LIPOLYSIS1964
- ANTIBODY-SUPPRESSIBLE AND NONSUPPRESSIBLE INSULIN-LIKE ACTIVITIES IN HUMAN SERUM AND THEIR PHYSIOLOGIC SIGNIFICANCE. AN INSULIN ASSAY WITH ADIPOSE TISSUE OF INCREASED PRECISION AND SPECIFICITY*JCI Insight, 1963